UNFO and OrthoPediatrics Join Forces to Launch Innovative Foot Braces for Newborns in the U.S.

UNFO and OrthoPediatrics Transform Newborn Foot Care

A significant breakthrough has emerged in the treatment of Metatarsus Adductus (MTA) thanks to a new partnership between UNFO Med Ltd. and OrthoPediatrics. For countless newborns diagnosed with this condition, which affects about 7% of infants, a painful journey through casting and surgeries could become a relic of the past.

UNFO Med Ltd., the creator of the Universal Neonatal Foot Orthotics (UNFO) system, has made headlines with the launch of a groundbreaking, FDA-approved corrective foot brace aimed specifically at addressing MTA. This orthopedic condition is characterized by the inward turning of the front part of the foot, often resulting from misalignments in the midfoot’s joints. The condition is hereditary, with a higher prevalence among siblings. If left untreated, affected infants can face long-term consequences ranging from foot deformities and chronic pain to developmental hip dysplasia and problematic gait issues.

Previously, the primary treatments for MTA included traditional casting, which severely limits mobility and causes distress for both infants and their parents, and invasive surgical procedures. These methods often demand multiple painful corrections over months, a taxing experience for families. However, the UNFO foot brace, developed by leading pediatric orthopedic surgeon Dr. Izak Daizade, aims to disrupt this cycle of discomfort through a more compassionate approach.

Dr. Daizade's experience, spanning over three decades in the field and ten years dedicated to this particular innovation, has led to the creation of a short orthotic device that is easy to wear under the ankle. The design allows for a comfortable fit, resembling a discreet sandal, while effectively correcting the intricate deformities caused by MTA. This innovation has already proven successful in treating over 15,000 infants, achieving a remarkable 95% success rate.

"Our collaboration with OrthoPediatrics signifies a transformative leap in the way we care for newborns afflicted with Metatarsus Adductus," stated Dr. Daizade, who is also CEO of UNFO Med Ltd. This partnership transcends mere technological progress; it embodies a major shift toward proactive and empathetic pediatric healthcare, ultimately sparing infants from unnecessary pain and trauma.

The UNFO brace is now available to pediatric practitioners and orthopedic specialists across the United States, positing itself as a beacon of hope for families navigating this challenging diagnosis. Parents interested in the UNFO system for their newborns can find additional details regarding the product's benefits and availability on the OrthoPediatrics website.

As UNFO Med Ltd. continues to pioneer innovations within pediatric orthopedic care, it stands committed to redefining treatment options and enhancing health outcomes for the youngest patients. With the collaboration with OrthoPediatrics, the aim is to hasten the transformation of early intervention practices in managing congenital foot conditions, ultimately improving the quality of life for many newborns.

In a healthcare landscape where timely and effective interventions are crucial, the introduction of the UNFO corrective brace represents not only advancement in treatment technology but also a reaffirmation of compassion in pediatric care.